Aspirex achieves 78% two-year primary patency rate in P-MAX postmarket observational study

At the Leipzig Interventional Course (LINC) 2024 (28–31 May, Leipzig, Germany), Michael Lichtenberg (Arnsberg Vascular Clinic, Arnsberg, Germany) shared for the first time a 24-month update from the P-MAX study of the Aspirex (BD) endovascular thrombectomy system in the treatment…
Nitinol stents placed in iliac veins “not associated with prolonged back pain,” study finds

In a retrospective review of over 600 patients who underwent iliac vein stent placement, the development of back pain was found to be unrelated to stent type, diameter, length or covered vein territory. Chloe Snow (Greenbelt, USA) and colleagues share…
AVeVA study confirms benefit of covered stent placement in graft-vein anastomotic stenosis treatment
A prospective, multicenter study involving the Covera vascular covered stent (BD) has confirmed the benefits of immediate, post-percutaneous transluminal angioplasty (PTA) placement of the device in treating arteriovenous graft (AVG) venous anastomotic stenosis when anatomically and clinically suitable. Writing in the Journal…
Venovo venous stent returns to US market after 2021 recall

BD recently announced that its Venovo venous stent is back on the U.S. market following a recall last year. In 2019, the company reported that the Food and Drug Administration (FDA) had granted premarket approval for the Venovo venous stent. In…
Database analysis findings ‘matched precisely’ with reported reasons for venous stent recalls

A recent analysis recalled Venovo and Vici venous stents—initiated last year—characterized “significant differences” between reported device and patient issues, and subsequent interventions for the two systems, with findings ultimately matching the reasons given for the recall at the time. A…
Boston Scientific and BD initiate venous stent recalls

Boston Scientific and BD have both initiated recalls of venous stents. According to a Food and Drug Administration (FDA) medical device recall notice posted May 21, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS…
Enrollment starts in postmarket studies of WavelinQ endoAVF system

Enrollment has begun and the first patients have been treated in the postmarket surveillance study, CONNECT-AV, of the WavelinQ (BD) endovascular arteriovenous fistula (endoAVF) system. CONNECT-AV is a prospective, single-arm, open-label study that will follow patients treated with WavelinQ (BD)…
BD acquires Straub Medical

Straub Medical, which manufactures, develops and sells medical devices for the treatment of arterial and venous diseases, has been acquired by Becton, Dickinson and Company (BD). Straub Medical devices are used worldwide by vascular surgeons and interventional specialists in radiology,…

